Identification of clinical risk factors for arrhythmia recurrence in patients with atrial fibrillation undergoing catheter ablation: A systematic review and meta-analysis.

Heart RhythmApr 29, 2026 (epub)
Clinical ResearchCardiology

Kimmy W P Chan, Doris S F Yu, Joshua W K Ho et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined clinical risk factors for arrhythmia recurrence in patients with atrial fibrillation (AF) post-catheter ablation, analyzing data from 152 studies with 49,919 patients. Key findings revealed that smoking (aHR 2.15) and periodontitis (aHR 2.04) were among the strongest predictors of recurrence, highlighting the importance of preablation risk assessment.

Key findings

  • Smoking was associated with a 2.15-fold increased risk of arrhythmia recurrence (aHR 2.15 [1.49-3.10]).
  • Periodontitis showed a 2.04-fold increased risk of recurrence (aHR 2.04 [1.48-2.83]).
  • Untreated sleep apnea conferred a heightened risk with an aHR of 2.41 (1.51-3.86).
  • Depression was linked to a 2.86-fold increased risk of recurrence (aOR 2.86 [1.51-5.41]).

Why it matters

Understanding the clinical risk factors for arrhythmia recurrence after AF ablation can guide clinicians in personalizing patient assessments and optimizing preprocedural interventions, potentially improving outcomes.

Source

Published in Heart Rhythm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.